# Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care

> **NCT05155917** · PHASE2 · UNKNOWN · sponsor: **Changhua Christian Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Hyperglycaemic Crisis in Diabetes Mellitus
- Diabetic Ketoacidosis
- Hyperglycaemic Hyperosmolar Nonketotic Syndrome

## Interventions

- **DRUG:** Insulin Glargine 300 UNT/ML [Toujeo]

## Key facts

- **NCT ID:** NCT05155917
- **Lead sponsor:** Changhua Christian Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-01
- **Primary completion:** 2024-01
- **Final completion:** 2024-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05155917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05155917, "Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05155917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*